|
|
Article: Is M&A The New IPO? Only For Some, Panel Says.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
MONTREAL - At a time when public markets often are unreceptive to small and midsize biotech companies, is merger and acquisition activity replacing initial public offerings as the preferred exit strategy for shareholders?
According to panelists at this year's VentureForum East meeting, in some ways it is, though M&A isn't always the best option for the industry as a whole.
While pedestrians strolled the sidewalks of downtown Montreal on a hot, sunny day, biotech executives and investors strolled the plush, air-conditioned hallways of the Marriott Chateau Champlain hotel on their way to presentations and one-on-one meetings. The ...